N. Ruperto Et Al. , "Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: results from the 5-year long-term extension of the phase III pivotal trials," ANNALS OF THE RHEUMATIC DISEASES , vol.77, no.12, pp.1710-1719, 2018
Ruperto, N. Et Al. 2018. Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: results from the 5-year long-term extension of the phase III pivotal trials. ANNALS OF THE RHEUMATIC DISEASES , vol.77, no.12 , 1710-1719.
Ruperto, N., Brunner, H. I., Quartier, P., Constantin, T., Wulffraat, N. M., Horneff, G., ... KASAPÇOPUR, Ö.(2018). Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: results from the 5-year long-term extension of the phase III pivotal trials. ANNALS OF THE RHEUMATIC DISEASES , vol.77, no.12, 1710-1719.
Ruperto, Nicolino Et Al. "Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: results from the 5-year long-term extension of the phase III pivotal trials," ANNALS OF THE RHEUMATIC DISEASES , vol.77, no.12, 1710-1719, 2018
Ruperto, Nicolino Et Al. "Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: results from the 5-year long-term extension of the phase III pivotal trials." ANNALS OF THE RHEUMATIC DISEASES , vol.77, no.12, pp.1710-1719, 2018
Ruperto, N. Et Al. (2018) . "Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: results from the 5-year long-term extension of the phase III pivotal trials." ANNALS OF THE RHEUMATIC DISEASES , vol.77, no.12, pp.1710-1719.
@article{article, author={Nicolino Ruperto Et Al. }, title={Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: results from the 5-year long-term extension of the phase III pivotal trials}, journal={ANNALS OF THE RHEUMATIC DISEASES}, year=2018, pages={1710-1719} }